Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PRU | Common Stock | Options Exercise | $0 | +13.6K | +171.96% | $0.00 | 21.4K | Feb 8, 2022 | Direct | F1, F2 |
transaction | PRU | Common Stock | Tax liability | -$508K | -4.18K | -19.52% | $121.33 | 17.2K | Feb 8, 2022 | Direct | F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PRU | 2022 Restricted Stock Units | Award | $0 | +5.15K | $0.00 | 5.15K | Feb 8, 2022 | Common Stock | 5.15K | $0.00 | Direct | F4, F5 | |
transaction | PRU | 2022 Performance Shares | Award | $0 | +15.5K | $0.00 | 15.5K | Feb 8, 2022 | Common Stock | 15.5K | $0.00 | Direct | F6, F7 | |
transaction | PRU | 2019 Performance Shares | Options Exercise | $0 | -7.23K | -100% | $0.00* | 0 | Feb 8, 2022 | Common Stock | 7.23K | $0.00 | Direct | F1 |
Id | Content |
---|---|
F1 | The Compensation Committee determined the number of shares received based on the Company's return on equity ("ROE") performance relative to a pre-determined goal and relative to the ROE performance of certain life insurance peer companies for the 2019 through 2021 performance period. |
F2 | Includes cash settled performance units which were converted from cash to equity settlement based on a decision by the Compensation Committee. |
F3 | Represents shares withheld for the payment of taxes. |
F4 | The Restricted Stock Units convert to common stock on a 1 to 1 basis. |
F5 | The Restricted Stock Units will vest 1/3 per year beginning on February 28, 2023. |
F6 | The performance shares convert to common stock on a 1 to 1 basis. |
F7 | Represents the target number of shares to be received. The actual number of shares to be received will be determined by the Compensation Committee in February 2025 based on the Company's ROE performance relative to certain life insurance peer companies and performance relative to a pre-determined goal for growth in adjusted book value per share for the 2022 through 2024 performance period. |